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Background: Real-world treatment patterns and survival outcomes of locally
advanced, unresectable, and metastatic urinary tract cancer (mUTC) patients have
not previously been studied in a nationwide, population-based cohort.
Objective: To describe treatment patterns and survival outcomes in mUTC patients
treated in the real-world clinical setting.
Design, setting, and participants: This nationwide, population-based study includ-
ed all mUTC patients initiating first-line chemotherapy at Danish oncology depart-
ments from January 2010 to March 2016. Data were retrospectively obtained from
electronic medical records.
Outcome measurements and statistical analysis: Outcome measurements were
descriptive. Kaplan-Meier was used for survival analysis.
Results and limitations: Of 952 patients included in the study, 46.2% initiated
standard gemcitabine/cisplatin (GC) and 21.1% gemcitabine/carboplatin (CaG); the
remaining patients initiated other treatment regimens. Median follow-up was
11.6 mo. The overall response rate and disease control rate were 43.0% and
61.7% in all patients, 51.4% and 69.1% in GC-treated patients, and 34.4% and
58.8% in CaG-treated patients, respectively. Median overall survival (OS) was
11.7 (95% confidence interval [CI]: 10.8–12.5) mo in all patients, 14.0 (95% CI:
12.5–15.5) mo in GC-treated patients, and 9.8 (95% CI: 8.7–10.9) mo in CaG-treated
patients. Limitations include the retrospective study design.. Department of Oncology, Copenhagen University Hospital, Rigshospitalet,
 Copenhagen Ø, Denmark. Tel. +45 35 45 07 82; Fax: +45 35 45 53 89.
j.omland@regionh.dk (L.H. Omland).* Corresponding author
Blegdamsvej 9, DK-2100
E-mail address: lise.hoehttp://dx.doi.org/10.1016/j.euros.2020.12.002
2666-1683/© 2020 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conclusions: Real-world mUTC patients are older and less fit than patients
enrolled in clinical trials; despite this, tumor responses and survival are com-
parable. Survival in our patient cohort is also comparable with that reported
from other real-world studies in this patient group.
Patient summary: We studied treatment patterns and survival in urinary tract
cancer patients receiving chemotherapy in the real-world clinical practice.
Survival in our patient cohort was comparable with that reported from clinical
trials and other real-world studies in this patient group.
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Urinary tract cancer (UTC) is defined as primary carcinomas
of the renal pelvis, ureter, bladder, and urethra of different
histologic subtypes. The most frequent tumor location is the
bladder. Of the tumors, 90% are urothelial carcinomas and
only a minority are squamous cell carcinomas, adenocarci-
nomas, small-cell neuroendocrine carcinomas, or other
tumors of variant histologies [1,2].
According to European Association of Urology and
European Society for Medical Oncology guidelines, cisplat-
in-based combination chemotherapy is the preferred first-
line treatment in patients with locally advanced, unresect-
able, and metastatic UTC (mUTC) with gemcitabine/
cisplatin (GC) and methotrexate/vinblastine/doxorubicin/
cisplatin (MVAC) being the most frequently used regimens
[2–6]. Efficacy of GC and MVAC are noninferior to each
other, but due to its more favorable toxicity profile, GC is
widely accepted as the standard first-line treatment
regimen [6]. However, approximately 50% of treated
patients are considered cisplatin ineligible mainly due to
renal insufficiency, poor performance status (PS), or
comorbidities [7,8]. For years, recommended treatment
for these patients has been carboplatin-based combination
chemotherapy [2,9,10]. Median overall survival (OS) in
clinical trials has been estimated to be 14, 15, and 9 mo for
patients treated with GC, MVAC, and carboplatin/gemcita-
bine (CaG), respectively [6,9]. However, patients enrolled in
clinical trials are generally younger and have less comor-
bidity than patients managed in routine clinical practice
[11], and therefore survival estimates from clinical trials
cannot be generalized to all clinical settings [12,13]. Recent-
ly, immune checkpoint inhibitors (ICIs) have been approved
as a first-line treatment option in cisplatin-ineligible
patients in Europe [14]. However, the use of first-line ICI
is restricted to a subgroup of PD-L1–positive patients [2].
To optimize treatment of mUTC patients, there is a need
for more valid data on treatment outcomes in the real-
world clinical setting, something that has not been studied
in a nationwide, population-based cohort so far [15–19].
We therefore conducted a large, nationwide, population-
based cohort study in all mUTC patients in Denmark
initiating first-line chemotherapy, in order to describe
patient characteristics, treatment patterns, tumor response,
and survival.2. Patients and methods
2.1. Setting
Approximately 1100 patients are diagnosed with invasive (stage  T1)
UTC in Denmark each year [20]. An estimated 30% of patients have de
novo muscle-invasive disease and 10–20% of patients with superficial
tumors eventually progress to muscle-invasive disease [21], but the
exact number of patients developing mUTC is unknown. Patients with
mUTC are treated in one of six specialized uro-oncology departments.
Danish residents are equally entitled to publicly financed health care
including oncologic treatment. Privately funded health care services are
limited and do not include oncologic treatment of UTC. All health care
data are stored electronically ensuring high data coverage, with few
patients lost to follow-up.
Treatment guidelines remained unchanged during the study period
(from January 1, 2010 to March 31, 2016) [22]. According to these
guidelines, cisplatin-eligible patients with creatinine clearance (CrCl)
>60 ml/min were treated with standard GC every 3rd week (cisplatin
70 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8),
whereas patients with CrCl of 50–60 ml/min initiated GC split course (GC
sc; cisplatin 70 mg/m2 administered on days 1 and 2 and gemcitabine
1000 mg/m2 on days 1 and 8). Cisplatin-ineligible patients were treated
with a 3-wk schedule of CaG (carboplatin AUC 4.5–5.0 on day 1 and
gemcitabine 1000 mg/m2 on days 1 and 8); if not considered platinum
eligible, patients could be treated with single-agent gemcitabine
(gemcitabine 1200–1250 mg/m2 on days 1 and 8) [22]. Patients with
small-cell neuroendocrine carcinomas were treated with carboplatin/
etoposide (CaEto; etoposide 100 mg/m2 and carboplatin AUC 5 on day
1 every 3rd week) [22]. According to guidelines, a maximum of six cycles
of treatment were administered.
ICIs were introduced in Denmark in 2018 as standard treatment for
selected patients and therefore not a treatment option in the study
period.
2.2. Study population and data collection
Patients were identified from treatment registers of the six oncology
departments and included if they met the following criteria: histologi-
cally verified mUTC, and initiation of first-line chemotherapy at Danish
oncology departments during the study period. The date of study
inclusion was defined as the date of first chemotherapy administration.
Patients were included irrespective of histologic subtype, prior
neoadjuvant/adjuvant chemotherapy, prior treatment in clinical proto-
col, or comorbidity including other malignancies.
Data were obtained from electronic medical records. Time of data
collection was December 2017 for one center, mid 2018 for one center,
and mid 2019 for the remaining four centers.
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tumor response
Eastern Cooperative Oncology Group (ECOG) PS was reported from the
consultation in which the decision of treatment regimen was made.
Tumors were considered as urothelial carcinomas if that was the
predominant histologic subtype. Squamous cell carcinomas and
adenocarcinomas were only considered as such, if the tumors solely
consisted of this histologic subtype. Tumors were registered as small-cell
neuroendocrine carcinomas if that was the predominant histologic
subtype. First-line chemotherapy was defined as the first chemotherapy
regimen administered after the diagnosis of mUTC. Patients were
categorized in treatment groups and compared according to the first-line
chemotherapy regimen initiated.
Tumor responses were evaluated by local radiologists using
computed tomography (CT) scans performed as part of routine clinical
practice. We report on tumor responses observed at the end of first-line
chemotherapy. The overall response rate (ORR) was defined as the
proportion of patients who had a complete response (CR) or a partial
response (PR) after therapy, whereas disease control rate (DCR) was
defined as the proportion of patients who had CR, PR, or stable disease.
2.4. Statistical analysis
Study inclusion date was defined as the date of start of first-line
chemotherapy. Time at risk was computed from study inclusion until
death, date of last contact (if the patient was no longer receiving care at
the oncology department), or date of data collection (if the patient was
still receiving care in the oncology department), whichever occurred
first. We used Kaplan-Meier analysis to construct survival curves and
estimate OS for the entire patient cohort and according to first-line
chemotherapy regimen initiated. In addition, we calculated OS
separately for men and women aged 70 and <70 yr. SPSS version
25.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis.
The study was approved by the Danish Patient Safety Authorities (file
no.: 3-3013-2222/1) and the Danish Data Protection Agency (file no.:
2012-58-0004), and was conducted according to the Declaration of
Helsinki.
3. Results
3.1. Patient characteristics at the time of study inclusion
Of the 952 patients included in the study, 440 (46.2%)
initiated GC as first-line treatment, 84 (8.8%) initiated GC sc,
and 201 (21.1%) initiated CaG; the remaining patients
initiated one of the other treatment options (Table 1). The
median age at the initiation of first-line chemotherapy was
69 (interquartile range [IQR]: 63–75) yr in the total cohort,
67 (IQR: 61–71) yr in GC-treated patients, 72 (IQR: 66–76) yr
in patients treated with CaG, and 76 (IQR: 70–78) yr in
patients receiving single-agent gemcitabine. Patients were
predominantly male. Of the patients, 69.5% had ECOG PS 0–
1 and 14.7% PS 2–3. Of GC-treated patients, 75.9% had PS 0–1
and 7.9% PS 2–3; among CaG-treated patients, 60.7% and
21.4% had PS 0–1 and PS 2–3, respectively (Table 1). In the
majority of patients (92.3%), the histologic subtype was
urothelial carcinoma, except for patients treated with CaEto,
in whom the dominant histologic subtype was small-cell
neuroendocrine carcinoma (74.3%). Metastases were most
commonly located in local lymph nodes (50.8%), distant
lymph nodes (30.6%), and lungs (27.6%).3.2. Tumor response
In all 952 patients, ORR was 43.0% and DCR was 61.7%. ORR
and DCR were 51.4% and 69.1% in GC-treated patients and
34.4% and 58.8% in CaG-treated patients, respectively
(Table 2).
3.3. Subsequent treatment lines
In the entire cohort, 303 patients (31.8%) received second-
line treatment, most often vinflunine. Of GC-treated and GC
sc–treated patients, 38.0% and 36.9%, respectively, had
second-line treatment (in the form of vinflunine in 69.5%
and 67.7% of patients, respectively). Among patients
receiving CaG, 24.4% subsequently received second-line
treatment, most frequently vinflunine (77.6%), and among
those treated with single-agent gemcitabine, 18.5% received
second-line treatment (51.7% vinflunine). The most com-
monly administered treatment regimen in 34.3% of CaEto-
treated patients receiving subsequent second-line treat-
ment was topotecan (50.0%). Of the 303 patients who
received second-line treatment, 76 (25.1%) subsequently
received third-line treatment, and of them, 14 (18.4%) also
received fourth-line treatment.
3.4. Overall survival
Among the 952 patients with mUTC treated with first-line
chemotherapy, 851 (89.4%) had died at the time of data
collection after a median follow-up of 11.6 (IQR: 6.3–23.0)
mo. Median OS was 11.7 (95% CI: 10.8–12.5) mo (Table 3
and Fig. 1). In patients treated with GC, median OS was 14.0
(95% CI: 12.5–15.5) mo; in patients receiving CaG, OS was
9.8 (95% CI: 8.7–10.9) mo, and in patients receiving single-
agent gemcitabine, OS was 7.5 (95% CI: 6.3–8.7) mo. OS in
patients receiving GC sc and CaEto was 13.0 (95% CI: 8.6–
17.5) and 13.5 (95% CI: 7.5–19.4) mo, respectively. In the
entire cohort, median OS in men and woman aged 70 yr
was 11.0 (95% CI: 9.2–12.7) and 10.5 (95% CI: 8.7–12.4) mo,
respectively; in men and women aged <70 yr, median OS
was 12.4 (95% CI: 11.1–13.6) and 13.2 (95% CI: 10.8–15.5)
mo, respectively.
4. Discussion
In this nationwide, population-based cohort study of mUTC
patients treated in the real-world clinical setting at Danish
oncology departments, we described patient characteris-
tics, tumor response, and survival according to the first-line
chemotherapy regimen initiated.
This is the first nationwide, population-based cohort
study on treatment patterns and survival in mUTC patients.
Complete inclusion of patients, the large patient number, as
well as the completeness of tumor response data and nearly
complete follow-up in terms of survival are major study
strengths. Another strength is access to detailed data from
electronic medical records, which minimizes the risk of
misclassification and enables detailed description of patient
characteristics and treatment outcomes.
Table 1 – Baseline characteristics of 952 patients with mUTC initiating first-line chemotherapy at Danish oncology departments during the
period from January 1, 2010 to March 31, 2016
All GC GC sc CaG Gem CaEto Other a
Patients, n (%) 952 (100.0) 440 (46.2) 84 (8.8) 201 (21.1) 157 (16.5) 35 (3.7) 35 (3.7)
Age, median (IQR) 69 (63–75) 67 (61–71) 68 (63–73) 72 (66–76) 76 (70–78) 69 (63–76) 63 (59–71)
Gender, n (%)
Male 686 (72.1) 339 (77.0) 64 (76.2) 131 (65.2) 104 (66.2) 25 (71.4) 23 (65.7)
Female 266 (27.9) 101 (23.0) 20 (23.8) 70 (34.8) 53 (33.8) 10 (28.6) 12 (34.3)
ECOG PS, n (%)
0 341 (35.8) 205 (46.6) 35 (41.7) 32 (15.9) 33 (21.0) 20 (57.1) 16 (45.7)
1 321 (33.7) 129 (29.3) 34 (40.5) 90 (44.8) 48 (30.6) 7 (20.0) 13 (37.1)
2 135 (14.2) 34 (7.7) 4 (4.8) 42 (20.9) 47 (29.9) 5 (14.3) 3 (8.6)
3 5 (0.5) 1 (0.2) 0 (0.0) 1 (0.5) 3 (1.9) 0 (0.0) 0 (0.0)
Unknown 150 (15.8) 71 (16.1) 11 (13.1) 36 (17.9) 26 (16.6) 3 (8.6) 3 (8.6)
Histology, n (%)
UC b 879 (92.3) 414 (94.1) 79 (94.0) 194 (96.5) 154 (98.0) 8 (22.9) 30 (85.7)
SCC 27 (2.8) 14 (3.2) 4 (4.8) 5 (2.5) 2 (1.3) 0 (0.0) 2 (5.7)
Adenocarcinoma 10 (1.1) 7 (1.6) 1 (1.2) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
SCN carcinoma 29 (3.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 26 (74.3) 3 (8.6)
Other 5 (0.5) 4 (0.9) 0 (0.0) 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0)
Unknown 2 (0.2) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0)
Primary tumor location, n (%)
Upper urinary tract 168 (17.6) 47 (10.7) 27 (32.1) 42 (20.9) 44 (28.0) 1 (2.9) 7 (20.0)
Bladder 767 (80.6) 382 (86.8) 56 (66.7) 155 (77.1) 113 (72.0) 34 (97.1) 27 (77.1)
Urethra 14 (1.5) 9 (2.0) 1 (1.2) 3 (1.5) 0 (0.0) 0 (0.0) 1 (2.9)
Unknown 3 (0.3) 2 (0.6) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
TNM stage c
T4bN0M0 66 (6.9) 32 (7.3) 6 (7.1) 8 (4.0) 19 (12.1) 1 (2.9) 0 (0.0)
Any T, N+, M0 186 (19.5) 92 (20.9) 25 (29.8) 26 (12.9) 31 (19.7) 5 (14.3) 7 (20.0)
Any T, Any N, M1 650 (68.3) 297 (67.5) 48 (57.1) 160 (79.6) 101 (64.3) 18 (51.4) 26 (74.3)
Any T, Any N, Mx 20 (2.1) 12 (2.7) 1 (1.2) 3 (1.5) 2 (1.3) 1 (2.9) 1 (2.9)
Unknown 30 (3.2) 7 (1.6) 4 (4.8) 4 (2.0) 4 (2.5) 10 (28.6) 1 (2.9)
Metastatic sites, n (%)
Local LN d 484 (50.8) 232 (52,7) 46 (54.8) 92 (45.8) 82 (52.2) 14 (40.0) 18 (51.4)
Distant LN e 291 (30.6) 145 (33.0) 15 (17.9) 82 (40.8) 34 (21.7) 5 (14.3) 10 (28.6)
Lungs 263 (27.6) 114 (25.9) 18 (21.4) 62 (30.8) 52 (33.1) 10 (28.6) 7 (20.0)
Liver 131 (13.8) 52 (11.8) 11 (13.1) 34 (16.9) 23 (14.6) 8 (22.9) 3 (8.6)
Bone 148 (15.5) 71 (16.1) 12 (14.3) 37 (18.4) 19 (12.1) 6 (17.1) 3 (8.6)
Brain 5 (0.5) 1 (0.2) 1 (1.2) 1 (0.5) 2 (1.3) 0 (0.0) 0 (0.0)
Other 129 (13.6) 48 (10.9) 13 (15.5) 36 (17.9) 21 (13.4) 4 (11.4) 7 (20.0)
Prior treatment, n (%)
Intravesical therapy 63 (6.6) 26 (5.9) 4 (4.8) 18 (9.0) 12 (7.6) 0 (0.0) 3 (8.6)
NAC 42 (4.4) 9 (2.0) 2 (2.4) 14 (7.0) 3 (1.9) 5 (14.3) 9 (25.7)
Cystectomy 269 (28.3) 134 (30.5) 27 (32.1) 46 (22.9) 42 (26.8) 6 (17.1) 14 (40.0)
NU 110 (11.6) 24 (5.5) 21 (25.0) 32 (15.9) 27 (17.2) 1 (2.9) 5 (14.3)
Curative RT 62 (6.5) 14 (3.2) 2 (2.4) 31 (15.4) 9 (5.7) 1 (2.9) 5 (14.3)
CaEto = carboplatin/etoposide; CaG = gemcitabine/carboplatin; ECOG PS = Eastern Cooperative Oncology Group performance status; GC = gemcitabine/cisplatin;
GC sc = gemcitabine/cisplatin split course; Gem = gemcitabine; IQR = interquartile range; LN = lymph nodes; mUTC = metastatic urinary tract cancer;
MVAC = methotrexate/vinblastine/doxorubicin/cisplatin; NAC = neoadjuvant chemotherapy; NU = nephroureterectomy; RT = radiotherapy; SCC = squamous cell
carcinoma; SCN carcinoma = small-cell neuroendocrine carcinoma; TNM = tumor, node, metastasis; UC = urothelial carcinoma.
a Other treatment regimens include MVAC, vinflunine/gemcitabine, cisplatin/gemcitabine/lapatinib, paclitaxel/carboplatin, paclitaxel/gemcitabine, and
docetaxel/cisplatin/5-FU (include protocol treatment).
b Predominant histologic subtype.
c At the start of first-line chemotherapy.
d Lymph nodes located in the abdomen.
e Lymph nodes located outside the abdomen.
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considerably higher than that of patients with mUTC in
previous clinical trials [5,23]. Accordingly, PS of patients
included in clinical trials were superior to that of patients
included in this real-world study [5,23]. These findings are
in line with previous studies describing patients enrolled in
clinical trials as younger and fitter than those treated in
routine clinical practice [12,13].
Most patients in our study received cisplatin-based
chemotherapy; a considerable proportion of the patientsreceived GC sc. This treatment regimen is used in Denmark
for patients with CrCl 50–60 ml/min and no other contra-
indications for cisplatin. This Danish practice is likely to
explain the widespread use of cisplatin in our patient
population, which exceeds that of other real-world settings
[24].
Contrary to what we expected, the CR rate among GC-
treated patients in our study was higher than what was
reported among GC-treated patients in previous clinical
trials [5,23]. This might be explained by the application of
Table 2 – Tumor responses at the end of first-line chemotherapy according to treatment type in 952 patients with locally advanced,
unresectable, and metastatic urinary tract cancer initiating first-line chemotherapy from January 1, 2010 to March 31, 2016
Tumor response All GC GC sc CaG Gem CaEto Other a
Complete response, n (%) 96 (10.1) 66 (15.0) 9 (10.7) 11 (5.5) 5 (3.2) 4 (11.4) 1 (2.9)
Partial response, n (%) 313 (32.9) 160 (36.4) 33 (39.3) 58 (28.9) 37 (23.6) 13 (37.1) 12 (34.3)
Stable disease, n (%) 178 (18.7) 78 (17.7) 10 (11.9) 49 (24.4) 25 (15.9) 9 (25.7) 7 (20.0)
Progressive disease, n (%) 233 (24.5) 88 (20.0) 20 (23.8) 50 (24.9) 56 (35.7) 8 (22.9) 11 (31.4)
Unknown, n (%) b 132 (13.9) 48 (10.9) 12 (14.3) 33 (16.4) 34 (21.7) 1 (2.9) 4 (11.4)
CaEto = carboplatin/etoposide; CaG = gemcitabine/carboplatin; GC = gemcitabine/cisplatin; GC sc = gemcitabine/cisplatin split course; Gem = gemcitabine;
MVAC = methotrexate/vinblastine/doxorubicin/cisplatin.
a Other treatment regimens include MVAC, vinflunine/gemcitabine, cisplatin/gemcitabine/lapatinib, paclitaxel/carboplatin, paclitaxel/gemcitabine, and
docetaxel/cisplatin/5-FU (include protocol treatment).
b Treatment responses unknown due to scans not performed after the last cycle of chemotherapy.
Table 3 – Median overall survival according to treatment type in
952 patients with locally advanced, unresectable, and metastatic
urinary tract cancer initiating first-line chemotherapy from
January 1, 2010 to March 31, 2016
No. of patients Median OS, mo (95% CI)
All 952 11.7 (10.8–12.5)
GC 440 14.0 (12.5–15.5)
GC sc 84 13.0 (8.6–17.5)
CaG 201 9.8 (8.7–10.9)
Gem 157 7.5 (6.3–8.7)
CaEto 35 13.5 (7.5–19.4)
Other a 35 13.4 (9.4–17.4)
CaEto = carboplatin/etoposide; CaG = gemcitabine/carboplatin;
GC = gemcitabine/cisplatin; GC sc = gemcitabine/cisplatin split course;
Gem = gemcitabine; MVAC = methotrexate/vinblastine/doxorubicin/
cisplatin; OS = overall survival.
a Other treatment regimens include MVAC, vinflunine/gemcitabine,
cisplatin/gemcitabine/lapatinib, paclitaxel/carboplatin, paclitaxel/
gemcitabine, and docetaxel/cisplatin/5-FU (include protocol treatment).






















Fig. 1 – Overall survival according to treatment type in 952 patients
with locally advanced, unresectable, and metastatic urinary tract cancer
initiating first-line chemotherapy from January 1, 2010 to March 31,
2016.
Other treatment regimens include MVAC, vinflunine/gemcitabine,
cisplatin/gemcitabine/lapatinib, paclitaxel/carboplatin, paclitaxel/
gemcitabine, and docetaxel/cisplatin/5-FU (include protocol treatment).
CaEto = carboplatin/etoposide; CaG = gemcitabine/carboplatin;
GC = gemcitabine/cisplatin; GC sc = gemcitabine/cisplatin split course;
Gem = gemcitabine; MVAC = methotrexate/vinblastine/doxorubicin/
cisplatin.
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settings [5,23]. However, tumor response among GC-treated
patients was also better in our study than what has
previously been demonstrated in a real-world setting in the
study by Niegisch et al [19] (CR rate 12%; Table 4).
OS among patients treated with GC (including GC sc) and
CaG was comparable with the results from two clinical trials
[6,9]. This is surprising, as survival is generally better in
clinical trials, but might be explained by the introduction of
second-line treatment after the clinical trials were carried
out. In our patient cohort, a considerable number of patients
received second-line treatment regardless of first-line
chemotherapy regimen and a minor proportion of patients
received subsequent lines of treatment.
Survival in our study exceeds that of several other real-
world studies on mUTC patients (Table 4): Galsky et al [16]
reported a median OS of 8.5 mo in the entire cohort of mUTC
patients and 12.1 mo in cisplatin-treated patients. However,
patients in the Galsky et al’s [16] study were considerably
older than the patients in the present study, which might
explain the differences in survival. Survival was also inferior
in the study by Robinson et al [17], which might be partly
explained by the study inclusion period (1994–2008), which
was before the introduction of second-line treatment
options. Other real-world studies have demonstrated
survival superior to what we demonstrated [15,19]. Thismight be explained by a more favorable distribution of risk
factors (age and PS) in these studies than in ours. To
summarize these findings, survival in real-world studies
seems to be associated with age and PS of the cohorts. In
Table 4, results from previously conducted real-world
studies and clinical trials in mUTC patients are summarized.
In our study population, 35 patients initiated first-line
CaEto; in the majority of these patients small-cell neuroen-
docrine carcinoma was the predominant histologic subtype.
Median OS in CaEto-treated patients was 13.5 (95% CI: 7.5–
19.4) mo, which is in line with a previous finding in this rare
subgroup of mUTC patients [25].
Although treatment options for mUTC have changed
with the introduction of ICIs, only a minority of patients are
eligible for this treatment option in the first-line setting,
and therefore valid data from a real-world setting on
patients treated with chemotherapy are still highly relevant.
The high number of patients receiving single-agent
gemcitabine indicates that many mUTC patients are
considered ineligible not only for cisplatin but also for
carboplatin. Some of these patients might have benefitted

















Type of study (real-world
studies vs clinical trials)
RW study RW study RW study RW study RW study RW study Clinical trial Clinical trial Clinical trial
No. of pts 1333 717 710 321 435 952 203 314 88
Age (median) 67.6 76 a 67 – 69 69 63 61 71
ECOG PS (%)
0 26.0 – – – 28.7 35.8 – b 54.5 17.0
1 38.8 – – – 50.1 33.7 – b 45.5 42.0
2 13.9 – – – 14.3 14.7 – b 0.0 40.9
1L treatment regimen (%)
Cisplatin based 50.2 26.8 54.5 37.7 71.0 55.0 100 100 0.0
GC – 21.3 36.8 26.5 63.4 46.2 100 100 0.0
Non–cisplatin based 49.8 73.2 45.5 62.3 29.0 45.0 0.0 0.0 100
CaG (%) – 31.5 13.5 36.8 10.8 21.1 0.0 0.0 100
ORR (CR/PR), (%)
All pts – – – – 34 (11/22) c 43.0 (10.1/32.9) 49.4 (12.2/37.2) c 43.6 (11.1/32.5) c 42.0 (3.4/38.6) c
Cisplatin-treated pts – – – – – 51.1 (14.3/36.8) 49.4 (12.2/37.2) c 43.6 (11.1/32.5) c –
GC-treated pts – – – – 35 (12/23) c 51.4 (15.0/36.4) 49.4 (12.2/37.2) c 43.6 (11.1/32.5)c –
CaG-treated pts – – – – – 34.3 (5.5/28.9) – – 42.0 (3.4/38.6) c
Median OS (mo)
All pts – 8.5 9 11.0 16.1 11.7 13.8 12.7 –
Cisplatin-treated pts 18 12.1 – 13.3 – – 13.8 12.7 –
GC-treated pts – – 10.0 – 17.7 14.0 d 13.8 12.7 –
Carboplatin-treated pts 12.5 – – 10.6 – 9.8 – – –
CaG-treated pts – – 7.4 – – 9.8 – – –
CaG=gemcitabine/carboplatin; CR= complete response; ECOG PS= Eastern Cooperative Oncology Group performance status; GC= gemcitabine/cisplatin; 1 L =first line; mUTC=metastatic urinary tract cancer; ORR=overall
response rate; OS =overall survival; PR =partial response; pts = patients; RW= real world.
a Median age at diagnosis of metastatic disease.
b Performance status reported as Karnofsky performance status.
c Best overall response rate.
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highlights the need for the development of new therapeutic
approaches.
Our study includes only patients initiating first-line
chemotherapy. An unknown number of mUTC patients are
found ineligible for systemic oncologic treatment at the
time of diagnosis. Efforts must be taken to characterize this
patient group and the reasons for treatment ineligibility, to
try to enable treatment for these patients.
This study has certain limitations. Owing to the
retrospective study design, missing data appear, particular-
ly regarding ECOG PS. No data on renal function, comorbid-
ities, laboratory values, toxicities, progression, and tumor
response at different time points were registered, which is
another shortcoming of the study. Finally, we cannot
completely exclude the possibility of an imaging bias
affecting our ORR, although this bias is likely to be of minor
importance only. Radiologists at Danish hospitals have
access to electronic medical records but are provided little
patient information before evaluation of scans.
5. Conclusions
Patients with mUTC treated in the real-world clinical setting
are older and less fit than patients included in clinical trials.
Despite this, tumor responses and survival are comparable
with those of patients enrolled in clinical trials. Survival in
our patient cohort is also comparable with the survival
outcomes in previously conducted real-world studies on
mUTC patients.
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